May 17, 2012
|
13.9 KB |
|
| |
LEXINGTON, Mass., May 17, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that several abstracts on its partnered programs have been accepted by the American Society of Clinical Oncology (ASCO) for presenta...
|
May 8, 2012
|
19.6 KB |
|
| |
LEXINGTON, Mass., May 8, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the first quarter ended March 31, 2012.
"The beginning of 2012 has been a period of continued progress w...
|
May 7, 2012
|
11.3 KB |
|
| |
LEXINGTON, Mass., May 7, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Roche has submitted an application for marketing registration for Erivedge™ (vismodegib) to Australia's T...
|
May 1, 2012
|
8.6 KB |
|
| |
LEXINGTON, Mass., May 1, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will release its first quarter financial results on Tuesday, May 8, 2012, before the market opens. The Company will also hold a conference ca...
|
Apr 30, 2012
|
8.8 KB |
|
| |
LEXINGTON, Mass., April 30, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will be presenting at the Deutsche Bank Securities 37th Annual Health Care Conference at 10:00 a.m. ET on May 7, 2012, in Boston.
Dan ...
|
Apr 13, 2012
|
8.8 KB |
|
| |
LEXINGTON, Mass., April 13, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will be presenting at the BioCentury Future Leaders in the Biotech Industry Conference at 2:00 p.m. ET on April 20, 2012, in New York City...
|
Apr 4, 2012
|
13.1 KB |
|
| |
LEXINGTON, Mass., April 4, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced the presentation of data in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago, Illinois. The poster pre...
|
Mar 28, 2012
|
8.9 KB |
|
| |
LEXINGTON, Mass., March 28, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will be presenting at the 11th annual Needham Healthcare Conference at 9:20 a.m. ET on April 4, 2012, in New York City.
Dan Passeri, P...
|
Mar 6, 2012
|
8.6 KB |
|
| |
LEXINGTON, Mass., March 6, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will be presenting at the Roth 24th Annual OC Growth Stock Conference at 11:30 a.m. PT on March 13, 2012, in Laguna Niguel, CA.
Dan Pas...
|
Feb 27, 2012
|
8.9 KB |
|
| |
LEXINGTON, Mass., Feb. 27, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will be presenting at the 32nd Annual Cowen and Company Health Care Conference at 1:30 p.m. EST on March 5, 2012, in Boston, MA.
Dan Pa...
|
Feb 21, 2012
|
8.6 KB |
|
| |
LEXINGTON, Mass., Feb. 21, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will be presenting at the 2012 RBC Capital Markets' Healthcare Conference at 1:35 p.m. EST on February 28, 2012, in New York City.
Dan ...
|
Feb 17, 2012
|
9.0 KB |
|
| |
LEXINGTON, Mass., Feb. 17, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will be presenting at the Citi 2012 Global Healthcare Conference at 4:00 p.m. EST on February 27, 2012, in New York City.
Dan Passeri, ...
|
Feb 16, 2012
|
51.2 KB |
|
| |
LEXINGTON, Mass., and LAUSANNE, Switzerland, Feb. 16, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, and Debiopharm Group (Debiopharm), a group of companies with a focus on the development of prescription drugs that target unmet medical needs, to...
|
Feb 8, 2012
|
25.3 KB |
|
| |
LEXINGTON, Mass., Feb. 8, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the fourth quarter and fiscal year ended December 31, 2011.
"With the recent FDA approval of Erivedge a...
|
Feb 6, 2012
|
9.0 KB |
|
| |
LEXINGTON, Mass., Feb. 6, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will be presenting at the 14th Annual BIO CEO & Investor Conference at 10:00 a.m. EST on February 13, 2012, in New York City.
Dan Passer...
|
Feb 1, 2012
|
8.7 KB |
|
| |
LEXINGTON, Mass., Feb. 1, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will release its fourth quarter financial results on Wednesday, February 8, 2012, before the market opens. The Company will also hold a conf...
|
Jan 30, 2012
|
17.4 KB |
|
| |
LEXINGTON, Mass., Jan. 30, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that Erivedge™ (vismodegib) capsule was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults w...
|
Dec 22, 2011
|
13.9 KB |
|
| |
LEXINGTON, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Roche has submitted a Marketing Authorization Application (MAA) for vismodegib (GDC-0449, RG3616) to the European Medicines A...
|
Dec 6, 2011
|
9.3 KB |
|
| |
LEXINGTON, Mass., Dec 06, 2011 (BUSINESS WIRE) --Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to
develop next generation targeted small molecule drug candidates for
cancer treatment, today announced that the Company will be presenting at
Oppenheimer & Company's 22nd Annual Healthcar...
|
Nov 30, 2011
|
13.3 KB |
|
| |
LEXINGTON, Mass., Nov 30, 2011 (BUSINESS WIRE) --Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to
develop next generation targeted small molecule drug candidates for
cancer treatment, today announced that the Company has entered into an
agreement under which The Leukemia & Lymphoma Society (LLS...
|
|
|
delicious
Digg
Facebook
LinkedIn
Twitter
Yahoo! Buzz
